Mitochondrial transporter expression patterns distinguish tumor from normal tissue and identify cancer subtypes with different survival and metabolism. Sci Rep. 2022 Oct 11; 12(1):17035.
View in:
PubMed
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 09 15; 28(18):4045-4055.
View in:
PubMed
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nat Commun. 2022 08 25; 13(1):4998.
View in:
PubMed
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022 09 12; 40(9):939-956.e16.
View in:
PubMed
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. Eur Urol. 2022 Sep; 82(3):247-251.
View in:
PubMed
Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. Eur J Cancer. 2022 07; 170:158-168.
View in:
PubMed
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. J Clin Oncol. 2022 Nov 01; 40(31):3633-3641.
View in:
PubMed
Blocking PI3K p110ß Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022 05 04; 20(5):673-685.
View in:
PubMed
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 09 01; 40(25):2913-2923.
View in:
PubMed
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc Natl Acad Sci U S A. 2022 04 05; 119(14):e2120403119.
View in:
PubMed
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 03 01; 28(5):831-839.
View in:
PubMed
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 02 15; 28(4):748-755.
View in:
PubMed
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
View in:
PubMed
Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190.
View in:
PubMed
Anti-CAIX BB? CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022 Mar 17; 24:385-399.
View in:
PubMed
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Res. 2022 01 15; 82(2):248-263.
View in:
PubMed
BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).
View in:
PubMed
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15; 21(1):1023.
View in:
PubMed
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904.
View in:
PubMed
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021 09 01; 27(17):4836-4847.
View in:
PubMed
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clin Cancer Res. 2021 05 15; 27(10):2868-2878.
View in:
PubMed
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
View in:
PubMed
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):649-661.e5.
View in:
PubMed
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243.
View in:
PubMed
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
View in:
PubMed
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 2021 01 20; 13(577).
View in:
PubMed
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
View in:
PubMed
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
View in:
PubMed
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 11; 8(2).
View in:
PubMed
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2020 Oct; 52(10):1132.
View in:
PubMed
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2021 01 01; 27(1):78-86.
View in:
PubMed
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 08 01; 6(8):1247-1255.
View in:
PubMed
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
View in:
PubMed
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
View in:
PubMed
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
View in:
PubMed
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019 12 01; 33(23-24):1718-1738.
View in:
PubMed
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
View in:
PubMed
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Mol Cancer Ther. 2020 02; 19(2):690-696.
View in:
PubMed
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Sci Signal. 2019 10 01; 12(601).
View in:
PubMed
Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
View in:
PubMed
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 10 15; 25(20):6080-6088.
View in:
PubMed
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2019 Jul 01; 25(13):4194.
View in:
PubMed
Corrigendum: Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2019 05 15; 28(10):1753-1754.
View in:
PubMed
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
View in:
PubMed
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019 04 08; 10(1):1617.
View in:
PubMed
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019 03 15; 363(6432):1217-1222.
View in:
PubMed
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
View in:
PubMed
Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2018 12 15; 27(24):4194-4203.
View in:
PubMed
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov. 2019 02; 9(2):230-247.
View in:
PubMed
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol. 2018 10 29; JCO2018792259.
View in:
PubMed
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018 09; 14(9):e1007679.
View in:
PubMed
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in:
PubMed
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12):3698.
View in:
PubMed
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018 07; 6(7):758-765.
View in:
PubMed
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348.
View in:
PubMed
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. Br J Cancer. 2018 05; 118(9):1238-1242.
View in:
PubMed
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 04 03; 23(1):313-326.e5.
View in:
PubMed
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):E3741-E3748.
View in:
PubMed
A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:203-210.
View in:
PubMed
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018 02; 50(2):206-218.
View in:
PubMed
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat Med. 2018 02; 24(2):165-175.
View in:
PubMed
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806.
View in:
PubMed
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436.
View in:
PubMed
In Reply. Oncologist. 2017 12; 22(12):1561.
View in:
PubMed
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. Kidney Cancer. 2017 Jul 26; 1(1):31-40.
View in:
PubMed
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci Transl Med. 2017 07 12; 9(398).
View in:
PubMed
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
View in:
PubMed
p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI Insight. 2017 May 04; 2(9).
View in:
PubMed
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017 10; 72(4):557-564.
View in:
PubMed
Renal cell carcinoma. Nat Rev Dis Primers. 2017 Mar 09; 3:17009.
View in:
PubMed
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765.
View in:
PubMed
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
View in:
PubMed
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503. Urol Oncol. 2017 03; 35(3):117-118.
View in:
PubMed
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2016 11 01; 126(11):4387.
View in:
PubMed
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Oct 20; 34(30):3655-3663.
View in:
PubMed
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017 May 01; 23(9):2159-2168.
View in:
PubMed
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 12; 65(12):1523-1532.
View in:
PubMed
On-target efficacy of a HIF-2a antagonist in preclinical kidney cancer models. Nature. 2016 11 03; 539(7627):107-111.
View in:
PubMed
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 08 26; 353(6302):929-32.
View in:
PubMed
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016 08 22; 17(1):174.
View in:
PubMed
Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genet. 2016 08; 12(8):e1006242.
View in:
PubMed
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869.
View in:
PubMed
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
View in:
PubMed
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell. 2016 Jun 30; 166(1):126-39.
View in:
PubMed
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
View in:
PubMed
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016 Jun 07; 7(23):34341-55.
View in:
PubMed
Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016 07; 48(7):725-32.
View in:
PubMed
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. 2016 May 24; 7(21):29901-15.
View in:
PubMed
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
View in:
PubMed
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
View in:
PubMed
Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. Clin Genitourin Cancer. 2016 12; 14(6):e585-e594.
View in:
PubMed
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
View in:
PubMed
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
View in:
PubMed
Corrigendum: Essential roles of PI(3)K-p110ß in cell growth, metabolism and tumorigenesis. Nature. 2016 05 12; 533(7602):278.
View in:
PubMed
Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. Cancer Cytopathol. 2015 Dec; 123(12):696-706.
View in:
PubMed
Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. Surg Pathol Clin. 2015 Dec; 8(4):587-621.
View in:
PubMed
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
View in:
PubMed
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
View in:
PubMed
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in:
PubMed
Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. Clin Genitourin Cancer. 2016 Feb; 14(1):e25-36.
View in:
PubMed
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol Cancer. 2015 Jun 11; 14:119.
View in:
PubMed
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43.
View in:
PubMed
Cell kinetic studies fail to identify sequentially proliferating progenitors as the major source of epithelial renewal in the adult murine prostate. PLoS One. 2015; 10(5):e0128489.
View in:
PubMed
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
View in:
PubMed
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
View in:
PubMed
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discov. 2015 May; 5(5):550-63.
View in:
PubMed
Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. Histopathology. 2015 May; 66(6):901-4.
View in:
PubMed
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
View in:
PubMed
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1925-1934.
View in:
PubMed
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015 Mar 01; 21(5):1071-7.
View in:
PubMed
Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014 Dec 22; 14:138.
View in:
PubMed
?Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Hum Pathol. 2015 Mar; 46(3):384-9.
View in:
PubMed
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8.
View in:
PubMed
PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184.
View in:
PubMed
RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015 Jan; 13(1):130-7.
View in:
PubMed
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014; 6(10):1357.
View in:
PubMed
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014 Aug 11; 26(2):222-34.
View in:
PubMed
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
View in:
PubMed
Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014; 9(8):e103325.
View in:
PubMed
D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev Cell. 2014 Aug 11; 30(3):255-67.
View in:
PubMed
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug; 4(8):896-904.
View in:
PubMed
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
View in:
PubMed
MET as a target in papillary renal cell carcinoma. Clin Cancer Res. 2014 Jul 01; 20(13):3361-3.
View in:
PubMed
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014 May 06; 19(5):795-809.
View in:
PubMed
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
View in:
PubMed
Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2a. Eur J Cancer. 2014 May; 50(8):1531-40.
View in:
PubMed
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 04; 6(4):519-38.
View in:
PubMed
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
View in:
PubMed
GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):1521-6.
View in:
PubMed
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013 Dec 09; 24(6):738-50.
View in:
PubMed
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell. 2013 Nov 07; 155(4):844-57.
View in:
PubMed
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013 Sep 15; 19(18):5218-26.
View in:
PubMed
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
View in:
PubMed
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013 Jul; 45(7):739-746.
View in:
PubMed
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul; 45(7):747-55.
View in:
PubMed
p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8105-10.
View in:
PubMed
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 01; 73(9):2718-36.
View in:
PubMed
Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):387.
View in:
PubMed
A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in:
PubMed
Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):260.
View in:
PubMed
Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol. 2013 Feb 20; 31(6_suppl):370.
View in:
PubMed
Identification of CDCP1 as a hypoxia-inducible factor 2a (HIF-2a) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2013 Feb 26; 110(9):3483-8.
View in:
PubMed
Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013 Feb; 14(2):105-7.
View in:
PubMed
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer. 2013 Feb 05; 108(2):319-26.
View in:
PubMed
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan; 3(1):44-51.
View in:
PubMed
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
View in:
PubMed
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol. 2013 Nov; 31(8):1788-93.
View in:
PubMed
The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012 Oct 16; 22(4):438-51.
View in:
PubMed
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2012 Dec; 2(12):1150-65.
View in:
PubMed
BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012 Nov; 62(5):917-22.
View in:
PubMed
The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. Mol Cell. 2012 Apr 13; 46(1):67-78.
View in:
PubMed
Assessment of a cell-line-derived HIF1a gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. J Clin Oncol. 2012 Feb 10; 30(5_suppl):408.
View in:
PubMed
Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):291.
View in:
PubMed
Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). J Clin Oncol. 2012 Feb 10; 30(5_suppl):352.
View in:
PubMed
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011 Dec 21; 9:220.
View in:
PubMed
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
View in:
PubMed
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86.
View in:
PubMed
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol. 2011 Oct; 225(2):212-21.
View in:
PubMed
Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Discov. 2011 Aug; 1(3):222-35.
View in:
PubMed
Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
View in:
PubMed
Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
View in:
PubMed
Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 May 20; 29(15_suppl):4568.
View in:
PubMed
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 Apr 29; 6(4):e19144.
View in:
PubMed
Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma. J Virol. 2011 Jun; 85(11):5581-92.
View in:
PubMed
RET protein expression in papillary renal cell carcinoma. Urol Oncol. 2012 Nov-Dec; 30(6):900-5.
View in:
PubMed
Pml represses tumour progression through inhibition of mTOR. EMBO Mol Med. 2011 May; 3(5):249-57.
View in:
PubMed
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73.
View in:
PubMed
Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int J Hyperthermia. 2011; 27(6):527-38.
View in:
PubMed
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010 Dec; 134(6):873-9.
View in:
PubMed
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010 Nov 16; 18(5):472-84.
View in:
PubMed
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010 Dec; 257(3):685-96.
View in:
PubMed
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010 Sep 07; 122(10):1004-16.
View in:
PubMed
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther. 2010 Oct; 9(10):2793-802.
View in:
PubMed
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010 Jul 15; 16(14):3628-38.
View in:
PubMed
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A. 2010 Jun 15; 107(24):11002-7.
View in:
PubMed
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8.
View in:
PubMed
The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
View in:
PubMed
Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010 Apr; 255(1):62-74.
View in:
PubMed
Risk of bilateral renal cell cancer. J Clin Oncol. 2009 Aug 10; 27(23):3737-41.
View in:
PubMed
p63 promotes cell survival through fatty acid synthase. PLoS One. 2009 Jun 11; 4(6):e5877.
View in:
PubMed
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009 Jun; 7(6):966-76.
View in:
PubMed
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81.
View in:
PubMed
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology. 2009 Jun; 251(3):731-42.
View in:
PubMed
Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. J Clin Oncol. 2009 May 20; 27(15_suppl):e16067.
View in:
PubMed
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51.
View in:
PubMed
Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009 May 15; 115(10 Suppl):2327-33.
View in:
PubMed
Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer. 2009 May 15; 115(10 Suppl):2290-7.
View in:
PubMed
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
View in:
PubMed
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther. 2009 Mar; 8(3):626-35.
View in:
PubMed
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55.
View in:
PubMed
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008 Jul; 191(1):133-9.
View in:
PubMed
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 07; 454(7205):776-9.
View in:
PubMed
Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res. 2008 Jun 15; 14(12):3699-705.
View in:
PubMed
Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008 Jun; 101 Suppl 4:31-5.
View in:
PubMed
Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):16042.
View in:
PubMed
Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders. J Clin Oncol. 2008 May 20; 26(15_suppl):5043.
View in:
PubMed
The association between overexpression of skp2 and the risk of recurrence following prostatectomy. J Clin Oncol. 2008 May 20; 26(15_suppl):11052.
View in:
PubMed
p63 in prostate biology and pathology. J Cell Biochem. 2008 Apr 01; 103(5):1354-68.
View in:
PubMed
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008 Mar; 10(3):361-9.
View in:
PubMed
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007 Sep; 5(6):379-85.
View in:
PubMed
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007 Aug; 244(2):464-70.
View in:
PubMed
High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
View in:
PubMed
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):758s-763s.
View in:
PubMed
Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol. 2007 Jan; 127(1):106-15.
View in:
PubMed
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006 Oct; 30(10):1281-91.
View in:
PubMed
Androgen-dependent regulation of Her-2/neu in prostate cancer cells. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10099.
View in:
PubMed
Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 01; 66(11):5723-8.
View in:
PubMed
Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology. 2006 Jul; 240(1):82-9.
View in:
PubMed
Prostate stem cells: from development to cancer. Semin Cancer Biol. 2007 Jun; 17(3):219-24.
View in:
PubMed
Defining cell lineages in the prostate epithelium. Cell Cycle. 2006 Jan; 5(2):138-41.
View in:
PubMed
Traumatic brain edema in diffuse and focal injury: cellular or vasogenic? Acta Neurochir Suppl. 2006; 96:24-9.
View in:
PubMed
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005 Aug 09; 102(32):11355-60.
View in:
PubMed
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2005 Jul 19; 102(29):10238-43.
View in:
PubMed
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21.
View in:
PubMed
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology. 2005 May; 235(2):469-77.
View in:
PubMed
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005 Apr 15; 65(8):3044-8.
View in:
PubMed
Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology. 2005 Apr; 235(1):81-8.
View in:
PubMed
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
View in:
PubMed
Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol. 2004 Aug; 31(7):477-82.
View in:
PubMed
Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4512.
View in:
PubMed
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004 Mar; 5(3):253-61.
View in:
PubMed
Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate. 2003 May 15; 55(3):206-18.
View in:
PubMed
Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol. 2002 Dec; 11(4):187-92.
View in:
PubMed
Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002 Dec; 15(12):1302-8.
View in:
PubMed
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 2002 Sep 12; 419(6903):162-7.
View in:
PubMed
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002 Sep; 110(5):633-41.
View in:
PubMed
Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 2002 Jun 13; 21(26):4099-107.
View in:
PubMed
Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002 Jan 01; 62(1):89-98.
View in:
PubMed
Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol. 2002 Jan; 22(2):635-43.
View in:
PubMed
Application of chemical shift imaging for measurement of NAA in head injured patients. Acta Neurochir Suppl. 2002; 81:373-5.
View in:
PubMed
Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol. 2001 Jul; 159(1):13-6.
View in:
PubMed
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001 May; 15(5):765-82.
View in:
PubMed
Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod Pathol. 2001 May; 14(5):437-42.
View in:
PubMed
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. J Pathol. 2001 Feb; 193(2):200-9.
View in:
PubMed
BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
View in:
PubMed
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 06; 92(23):1918-25.
View in:
PubMed
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000 Dec; 20(23):8969-82.
View in:
PubMed
p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000 Dec; 157(6):1769-75.
View in:
PubMed
Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep; 106(6):753-61.
View in:
PubMed
Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. J Cutan Pathol. 2000 May; 27(5):228-34.
View in:
PubMed
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000 Apr 15; 60(8):2095-100.
View in:
PubMed
Distinguishing between cellular and vasogenic edema in head injured patients with focal lesions using magnetic resonance imaging. Acta Neurochir Suppl. 2000; 76:349-51.
View in:
PubMed
Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. Diagn Mol Pathol. 1999 Dec; 8(4):176-82.
View in:
PubMed
Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. Hum Pathol. 1999 Nov; 30(11):1361-6.
View in:
PubMed
The surgical treatment of pituitary adenomas in the eighth decade. Surg Neurol. 1999 Mar; 51(3):261-6; discussion 266-7.
View in:
PubMed
Melanocytic nevi of palms and soles: a histological study according to the plane of section. Am J Surg Pathol. 1999 Mar; 23(3):283-7.
View in:
PubMed
Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol. 1999 Jan; 154(1):67-75.
View in:
PubMed
Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998 Apr 15; 58(8):1730-5.
View in:
PubMed
Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Pathol. 1998 Apr; 51(2):113-4.
View in:
PubMed
Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol. 1997 Nov; 21(11):1307-15.
View in:
PubMed
Neutrophilic figurate erythema of infancy. Am J Dermatopathol. 1997 Aug; 19(4):403-6.
View in:
PubMed
Papular clear cell hyperplasia of the eccrine duct in a diabetic. Br J Dermatol. 1996 Jul; 135(1):139-43.
View in:
PubMed
Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther. 1996 Feb; 3(2):145-53.
View in:
PubMed